DOCSLIB.ORG

Insulin and Amylin Release Are Both Diminished in First-Degree Relatives of Subjects with Type 2 Diabetes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Insulin and Amylin Release Are Both Diminished in First-Degree Relatives of Subjects with Type 2 Diabetes Epidemiology/Health Services/Psychosocial Research ORIGINAL ARTICLE Insulin and Amylin Release Are Both Diminished in First-Degree Relatives of Subjects With Type 2 Diabetes NEGAR G. KNOWLES, MA WILFRED Y. FUJIMOTO, MD ease these changes occur. A number of MELINDA A. LANDCHILD, MA STEVEN E. KAHN, MB, CHB studies have been largely interpreted to suggest that whereas insulin resistance exists in individuals who are at high risk of developing diabetes and have normal glucose tolerance, ␤-cell function is not OBJECTIVE — To determine whether first-degree relatives of individuals with type 2 diabe- ␤ ␤ diminished (6–9), or if -cell dysfunction tes, who are at high risk of subsequently developing hyperglycemia, manifest alterations in -cell is present, this dysfunction is only mild function including an alteration in the co-release of insulin and amylin. and is present only when impaired glu- RESEARCH DESIGN AND METHODS — In 30 first-degree relatives and 24 matched cose tolerance exists (10,11). However, subjects with no family history of diabetes, ␤-cell function was measured as the intravenous these assessments have not accounted for glucose–induced acute insulin response (AIRg) and acute amylin response (AARg). The insulin the fact that insulin sensitivity is an im- sensitivity index (SI) was quantified and used to account for the role of insulin sensitivity to portant modulator of the ␤-cell response ␤ ϫ␤ modulate -cell function (SI -cell function). to secretagogues, and therefore reduced ␤-cell function may easily be overlooked RESULTS — Fasting plasma glucose (5.3 Ϯ 0.1 vs. 5.1 Ϯ 0.1 mmol/l; means Ϯ SEM), Ϯ Ϯ (12,13). Thus, when the effect of insulin immunoreactive insulin (IRI) (68 7 vs. 57 6 pmol/l) and amylin-like immunoreactivity ␤ (ALI) (5.5 Ϯ 0.6 vs. 4.7 Ϯ 0.7 pmol/l) were similar in relatives and control subjects, respectively. sensitivity on -cell function is accounted Ϯ Ϯ for, a comparable insulin response could Relatives were insulin resistant compared with control subjects (SI: 4.86 0.63 vs. 7.20 ϫ Ϫ5 Ϫ1 ⅐ Ϫ1 ⅐ Ϫ1 ϭ Ϯ Ϯ 0.78 10 min pmol l , P 0.01), but their AIRg (392 59 vs. 386 50 pmol/l) in fact be considered inappropriately low Ϯ Ϯ ␤ and AARg (5.9 0.9 vs. 6.1 0.8 pmol/l) did not differ. When -cell function was determined in the face of insulin resistance. Using this ϫ Ϯ relative to insulin sensitivity, in the first-degree relatives, both AIRg (SI AIRg: 1.60 0.23 vs. approach, it is now being recognized that Ϯ ϫ Ϫ2 Ϫ1 Ͻ ϫ Ϯ Ϯ ϫ 2.44 0.31 10 min , P 0.05) and AARg (SI AARg: 2.39 0.35 vs. 4.06 0.56 ␤-cell function is relatively decreased in 10Ϫ4 minϪ1, P Ͻ 0.05) were reduced. The molar proportion of ALI to IRI was not altered in Ϯ Ϯ some groups at high risk of developing high-risk subjects (1.75 0.16 vs. 1.71 0.15%). hyperglycemia (14–18). Amylin is a 37–amino acid peptide CONCLUSIONS — First-degree relatives of subjects with type 2 diabetes have diminished ␤ ␤-cell function at a time when they are not hyperglycemic, and this reduction affects insulin and that is produced by the -cell and is co- amylin responses proportionally. Thus, an altered amylin-to-insulin ratio is not likely to identify secreted with insulin in response to glucose individuals at high risk of developing type 2 diabetes. and nonglucose secretagogues adminis- tered orally or intravenously (4,5,19,20). Diabetes Care 25:292–297, 2002 It is the unique constituent of the islet amyloid deposits found in the vast major- ity of subjects with type 2 diabetes (21– he pathogenesis of type 2 diabetes ␤-cell peptide known as amylin or islet 23). We and others have hypothesized includes reductions in insulin sensi- amyloid polypeptide can also be demon- that alterations in the handling of this T tivity and ␤-cell function (1). The strated in subjects with type 2 diabetes peptide by the ␤-cell may underlie the change in ␤-cell function has been dem- (3–5). propensity of diabetic individuals to de- onstrated to include a reduction in insulin Although the changes in insulin sen- posit amyloid, resulting in a reduction in secretion in response to glucose (2). In sitivity and ␤-cell function have been ␤-cell mass and the loss of ␤-cell secretory addition to this reduction in insulin re- demonstrated to exist once hyperglyce- capacity (24). In keeping with a reduction lease, it is apparent that a decrease in the mia is present, it has been debated as to in ␤-cell secretory capacity, we have ob- release of the more recently described when during the development of the dis- served reductions in insulin and amylin responses in individuals with impaired ●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● glucose tolerance (5). Others have found From the Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound that the amylin response is increased un- Health Care System, and the University of Washington, Seattle, Washington. Address correspondence and reprint requests to Steven E. Kahn, MB, ChB, VA Puget Sound Health Care der conditions associated with insulin System (151), 1660 S. Columbian Way, Seattle, WA 98108. E-mail: [email protected]. resistance, such as obesity (4,25) and Received for publication 27 July 2001 and accepted in revised form 4 November 2001. pregnancy (26), including in women with Abbreviations: AARg, intravenous glucose–induced acute amylin response; AIRg, intravenous glucose– gestational diabetes who are at high risk induced acute insulin response; ALI, amylin-like immunoreactivity; GEZI, glucose effectiveness at zero for subsequently developing type 2 diabe- insulin; IRI, immunoreactive insulin; SG, glucose effectiveness; SI, insulin sensitivity index. A table elsewhere in this issue shows conventional and Syste`me International (SI) units and conversion tes. Thus, changes in amylin have been factors for many substances. observed under scenarios that are associ- 292 DIABETES CARE, VOLUME 25, NUMBER 2, FEBRUARY 2002 Knowles and Associates ated with an increased risk of developing Table 1—Demographic characteristics and fasting plasma glucose, IRI, and ALI concentra- type 2 diabetes. tions in first-degree relatives of type 2 diabetic subjects and in control subjects First-degree relatives of subjects with type 2 diabetes are at increased risk of First-degree relatives Control subjects developing hyperglycemia. They there- fore provide an ideal group to study to n 30 24 determine the magnitude of changes in Age (years) 39.8 Ϯ 1.7 42.0 Ϯ 3.1 insulin sensitivity and ␤-cell function that BMI (kg/m2) 29.2 Ϯ 1.2 26.7 Ϯ 0.8 may be present in such high-risk individ- Fasting glucose (mmol/l) 5.3 Ϯ 0.1 5.1 Ϯ 0.1 uals. Furthermore, as they are at increased Fasting IRI (pmol/l) 68 Ϯ 757Ϯ 6 risk of developing hyperglycemia, they Fasting ALI (pmol/l) 5.5 Ϯ 0.6 4.7 Ϯ 0.7 also represent an appropriate cohort for Data are means Ϯ SEM. examining whether amylin responses are altered in high-risk subjects. Therefore, were obtained 2, 3, 4, 5, 6, 8, 10, 12, 14, as the insulin sensitivity index (SI) and we have examined a group of first-degree 16, 19, 22, 23, 24, 25, 27, 30, 35, 40, 50, glucose effectiveness at basal insulin (SG) relatives of subjects with type 2 diabetes 60, 70, 80, 90, 100, 120, 140, 160, 180, (28). Glucose effectiveness at zero insulin ϭ Ϫ ϫ and a control group and quantified insu- 200, 220, and 240 min after glucose ad- [GEZI SG (SI fasting IRI)] was cal- lin sensitivity and both insulin and amylin ministration. The administration of tol- culated as a measure of insulin-indepen- responses as measures of ␤-cell function butamide and the prolonged sampling dent glucose disposal (31). The in these individuals to determine whether schedule served to improve the ability to intravenous glucose–induced acute insu- these variables are altered in these high- identify the parameters (27) when the lin (AIRg) and acute amylin (AARg)re- risk subjects. In the process, we also ex- glucose and insulin data were analyzed sponses were calculated as the mean amined whether differential alterations in using the minimal model of glucose kinet- incremental response above basal from insulin and amylin responses may pro- ics developed by Bergman et al. (28). All the samples drawn during the first 10 min vide an additional useful marker for sub- samples were assayed for glucose and in- after intravenous glucose administration. jects at high risk of developing type 2 sulin, whereas only the basal samples and The percentile ranking for each individu- diabetes. those drawn up to 10 min after glucose al’s product of SI and AIRg (disposition injection were assayed for amylin. index) was determined using the formula RESEARCH DESIGN AND ␣ϭ ϫ ϩ METHODS Assays Z [ln(SI AIRg) 3.802]/0.5613 All blood samples were drawn into tubes Subjects containing EDTA, kept on ice before sep- which was originally determined by our The groups consisted of 30 (9 males/21 aration, and subsequently stored at Ϫ70°C group in a cohort of 93 apparently healthy females) individuals with at least one first- before being assayed. Plasma glucose was subjects (13). degree relative with a known diagnosis of measured by an automated glucose oxi- The glucose disappearance constant type 2 diabetes and 24 (14 males/10 fe- dase method. Plasma immunoreactive was calculated as the slope of the regres- males) subjects who had no known family insulin (IRI) was measured by a radioim- sion line relating the natural log of the history of type 2 diabetes.
Load more

Recommended publications
  • Protection of Insulin‑Like Growth Factor 1 on Experimental Peripheral Neuropathy in Diabetic Mice
    MOLECULAR MEDICINE REPORTS 18: 4577-4586, 2018 Protection of insulin‑like growth factor 1 on experimental peripheral neuropathy in diabetic mice HUA WANG, HAO ZHANG, FUMING CAO, JIAPING LU, JIN TANG, HUIZHI LI, YIYUN ZHANG, BO FENG and ZHAOSHENG TANG Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, P.R. China Received December 24, 2017; Accepted July 19, 2018 DOI: 10.3892/mmr.2018.9435 Abstract. The present study investigated whether insulin-like the IGF-1-PPP group compared with the IGF-1 group; however, growth factor-1 (IGF-1) exerts a protective effect against no significant difference was observed in the expression neuropathy in diabetic mice and its potential underlying levels of p-p38 following treatment with IGF-1. The results mechanisms. Mice were divided into four groups: Db/m of the present study demonstrated that IGF-1 may improve (control), db/db (diabetes), IGF-1-treated db/db and neuropathy in diabetic mice. This IGF-1-induced neurotrophic IGF-1-picropodophyllin (PPP)-treated db/db. Behavioral effect may be associated with the increased phosphorylation studies were conducted using the hot plate and von Frey levels of JNK and ERK, not p38; however, it was attenuated by methods at 6 weeks of age prior to treatment. The motor nerve administration of an IGF-1R antagonist. conduction velocity (NCV) of the sciatic nerve was measured using a neurophysiological method at 8 weeks of age. The Introduction alterations in the expression levels of IGF-1 receptor (IGF-1R), c-Jun N-terminal kinase (JNK), extracellular signal-regulated An epidemiological survey demonstrated that the prevalence kinase (ERK), p38 and effect of IGF-1 on the sciatic nerve of diabetes in adults ≥18 years old in China was ≤11.6% (1).
    [Show full text]
  • Receptor Activity Modifying Proteins (Ramps) Interact with the VPAC2 Receptor and CRF1 Receptors and Modulate Their Function
    British Journal of DOI:10.1111/j.1476-5381.2012.02202.x www.brjpharmacol.org BJP Pharmacology RESEARCH PAPER Correspondence David R Poyner, School of Life and Health Sciences, Aston University, Birmingham, Receptor activity modifying B4 7ET, UK. E-mail: [email protected] ---------------------------------------------------------------- proteins (RAMPs) interact Current address: *Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, 381 with the VPAC2 receptor Royal Parade, Parkville, Victoria 3052 Australia; †Discovery Sciences, AstraZeneca R&D, and CRF1 receptors and Mölndal, Sweden; ‡R&I iMED, AstraZeneca R&D, Mölndal, Sweden. modulate their function ---------------------------------------------------------------- Keywords D Wootten1*, H Lindmark2†, M Kadmiel3, H Willcockson3, KM Caron3, receptor activity-modifying proteins (RAMPs); RAMP1; J Barwell1, T Drmota2‡ and DR Poyner1 RAMP2; RAMP3; VPAC2 receptor; +/- CRF1 receptor; Ramp2 mice; 1 2 School of Life and Health Sciences, Aston University, Birmingham, UK, Department of Lead G-protein coupling; biased Generation, AstraZeneca R&D, Mölndal, Sweden, and 3Department of Cellular and Molecular agonism Physiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA ---------------------------------------------------------------- Received 10 July 2012 Revised 15 August 2012 Accepted 28 August 2012 BACKGROUND AND PURPOSE Although it is established that the receptor activity modifying proteins (RAMPs) can interact with a number of GPCRs, little is known about the consequences of these interactions. Here the interaction of RAMPs with the glucagon-like peptide 1 receptor (GLP-1 receptor), the human vasoactive intestinal polypeptide/pituitary AC-activating peptide 2 receptor (VPAC2) and the type 1 corticotrophin releasing factor receptor (CRF1) has been examined. EXPERIMENTAL APPROACH GPCRs were co-transfected with RAMPs in HEK 293S and CHO-K1 cells.
    [Show full text]
  • Type 1 Diabetes Autoantigen Epitope in the Pathogenesis of Junction of Proinsulin Is an Early Evidence That a Peptide Spanning T
    Evidence That a Peptide Spanning the B-C Junction of Proinsulin Is an Early Autoantigen Epitope in the Pathogenesis of Type 1 Diabetes This information is current as of September 24, 2021. Wei Chen, Isabelle Bergerot, John F. Elliott, Leonard C. Harrison, Norio Abiru, George S. Eisenbarth and Terry L. Delovitch J Immunol 2001; 167:4926-4935; ; doi: 10.4049/jimmunol.167.9.4926 Downloaded from http://www.jimmunol.org/content/167/9/4926 References This article cites 50 articles, 24 of which you can access for free at: http://www.jimmunol.org/content/167/9/4926.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 24, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Evidence That a Peptide Spanning the B-C Junction of Proinsulin Is an Early Autoantigen Epitope in the Pathogenesis of Type 1 Diabetes1 Wei Chen,2* Isabelle Bergerot,2* John F.
    [Show full text]
  • Sulfatide Preserves Insulin Crystals Not by Being Integrated in the Lattice but by Stabilizing Their Surface
    Hindawi Publishing Corporation Journal of Diabetes Research Volume 2016, Article ID 6179635, 4 pages http://dx.doi.org/10.1155/2016/6179635 Research Article Sulfatide Preserves Insulin Crystals Not by Being Integrated in the Lattice but by Stabilizing Their Surface Karsten Buschard,1 Austin W. Bracey,2 Daniel L. McElroy,2 Andrew T. Magis,2 Thomas Osterbye,1 Mark A. Atkinson,2 Kate M. Bailey,2 Amanda L. Posgai,2 and David A. Ostrov2 1 Bartholin Instituttet, Rigshospitalet, 2100 Copenhagen, Denmark 2Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, 1600 SW Archer Road, Gainesville, FL 32610, USA Correspondence should be addressed to Karsten Buschard; [email protected] Received 30 October 2015; Revised 14 January 2016; Accepted 14 January 2016 Academic Editor: Fabrizio Barbetti Copyright © 2016 Karsten Buschard et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Sulfatide is known to chaperone insulin crystallization within the pancreatic beta cell, but it is not known if this results from sulfatide being integrated inside the crystal structure or by binding the surface of the crystal. With this study, we aimed to characterize the molecular mechanisms underlying the integral role for sulfatide in stabilizing insulin crystals prior to exocytosis. Methods. We cocrystallized human insulin in the presence of sulfatide and solved the structure by molecular replacement. Results. The crystal structure of insulin crystallized in the presence of sulfatide does not reveal ordered occupancy representing sulfatide in the crystal lattice, suggesting that sulfatide does not permeate the crystal lattice but exerts its stabilizing effect by alternative interactions such as on the external surface of insulin crystals.
    [Show full text]
  • Alteration in Phosphorylation of P20 Is Associated with Insulin Resistance Yu Wang,1 Aimin Xu,1 Jiming Ye,2 Edward W
    Alteration in Phosphorylation of P20 Is Associated With Insulin Resistance Yu Wang,1 Aimin Xu,1 Jiming Ye,2 Edward W. Kraegen,2 Cynthia A. Tse,1 and Garth J.S. Cooper1,3 We have recently identified a small phosphoprotein, P20, insulin action, such as the activation of insulin receptors, as a common intracellular target for insulin and several postreceptor signal transduction, and the glucose trans- of its antagonists, including amylin, epinephrine, and cal- port effector system, have been implicated in this disease citonin gene-related peptide. These hormones elicit phos- (3,4). Defective insulin receptor kinase activity, reduced phorylation of P20 at its different sites, producing three insulin receptor substrate-1 tyrosine phosphorylation, and phosphorylated isoforms: S1 with an isoelectric point (pI) decreased phosphatidylinositol (PI)-3 kinase activity were value of 6.0, S2 with a pI value of 5.9, and S3 with a pI observed in both human type 2 diabetic patients as well as value of 5.6 (FEBS Letters 457:149–152 and 462:25–30, animal models, such as ob/ob mice (5,6). 1999). In the current study, we showed that P20 is one In addition to the intrinsic defects of the insulin receptor of the most abundant phosphoproteins in rat extensor digitorum longus (EDL) muscle. Insulin and amylin an- and postreceptor signaling components, other circulating tagonize each other’s actions in the phosphorylation of factors, such as tumor necrosis factor-␣, leptin, free fatty this protein in rat EDL muscle. Insulin inhibits amylin- acids, and amylin, may also contribute to the pathogenesis evoked phosphorylation of S2 and S3, whereas amylin of insulin resistance (7–11).
    [Show full text]
  • A Plant-Based Meal Increases Gastrointestinal Hormones
    nutrients Article A Plant-Based Meal Increases Gastrointestinal Hormones and Satiety More Than an Energy- and Macronutrient-Matched Processed-Meat Meal in T2D, Obese, and Healthy Men: A Three-Group Randomized Crossover Study Marta Klementova 1, Lenka Thieme 1 , Martin Haluzik 1, Renata Pavlovicova 1, Martin Hill 2, Terezie Pelikanova 1 and Hana Kahleova 1,3,* 1 Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic; [email protected] (M.K.); [email protected] (L.T.); [email protected] (M.H.); [email protected] (R.P.); [email protected] (T.P.) 2 Institute of Endocrinology, 113 94 Prague, Czech Republic; [email protected] 3 Physicians Committee for Responsible Medicine, Washington, DC 20016, USA * Correspondence: [email protected]; Tel.: +1-202-527-7379 Received: 6 December 2018; Accepted: 9 January 2019; Published: 12 January 2019 Abstract: Gastrointestinal hormones are involved in regulation of glucose metabolism and satiety. We tested the acute effect of meal composition on these hormones in three population groups. A randomized crossover design was used to examine the effects of two energy- and macronutrient-matched meals: a processed-meat and cheese (M-meal) and a vegan meal with tofu (V-meal) on gastrointestinal hormones, and satiety in men with type 2 diabetes (T2D, n = 20), obese men (O, n = 20), and healthy men (H, n = 20). Plasma concentrations of glucagon-like peptide -1 (GLP-1), amylin, and peptide YY (PYY) were determined at 0, 30, 60, 120 and 180 min. Visual analogue scale was used to assess satiety. We used repeated-measures Analysis of variance (ANOVA) for statistical analysis.
    [Show full text]
  • Isolation and Proteomics of the Insulin Secretory Granule
    H OH metabolites OH Review Isolation and Proteomics of the Insulin Secretory Granule Nicholas Norris , Belinda Yau * and Melkam Alamerew Kebede Charles Perkins Centre, School of Medical Sciences, University of Sydney, Camperdown, NSW 2006, Australia; [email protected] (N.N.); [email protected] (M.A.K.) * Correspondence: [email protected] Abstract: Insulin, a vital hormone for glucose homeostasis is produced by pancreatic beta-cells and when secreted, stimulates the uptake and storage of glucose from the blood. In the pancreas, insulin is stored in vesicles termed insulin secretory granules (ISGs). In Type 2 diabetes (T2D), defects in insulin action results in peripheral insulin resistance and beta-cell compensation, ultimately leading to dysfunctional ISG production and secretion. ISGs are functionally dynamic and many proteins present either on the membrane or in the lumen of the ISG may modulate and affect different stages of ISG trafficking and secretion. Previously, studies have identified few ISG proteins and more recently, proteomics analyses of purified ISGs have uncovered potential novel ISG proteins. This review summarizes the proteins identified in the current ISG proteomes from rat insulinoma INS-1 and INS-1E cell lines. Here, we also discuss techniques of ISG isolation and purification, its challenges and potential future directions. Keywords: insulin secretory granule; beta-cells; granule protein purification 1. Insulin Granule Biogenesis and Function Citation: Norris, N.; Yau, B.; Kebede, The insulin secretory granule (ISG) is the storage vesicle for insulin in pancreatic M.A. Isolation and Proteomics of the beta-cells. It was long treated as an inert carrier for insulin but is now appreciated as a Insulin Secretory Granule.
    [Show full text]
  • Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes
    258 Diabetes Care Volume 42, February 2019 Proinsulin Secretion Is a Emily K. Sims,1,2 Henry T. Bahnson,3 Julius Nyalwidhe,4 Leena Haataja,5 Persistent Feature of Type 1 Asa K. Davis,3 Cate Speake,3 Linda A. DiMeglio,1,2 Janice Blum,6 Diabetes Margaret A. Morris,7 Raghavendra G. Mirmira,1,2,8,9,10 7 10,11 Diabetes Care 2019;42:258–264 | https://doi.org/10.2337/dc17-2625 Jerry Nadler, Teresa L. Mastracci, Santica Marcovina,12 Wei-Jun Qian,13 Lian Yi,13 Adam C. Swensen,13 Michele Yip-Schneider,14 C. Max Schmidt,14 Robert V. Considine,9 Peter Arvan,5 Carla J. Greenbaum,3 Carmella Evans-Molina,2,8,9,10,15 and the T1D Exchange Residual C-peptide Study Group* OBJECTIVE Abnormally elevated proinsulin secretion has been reported in type 2 and early type 1 diabetes when significant C-peptide is present. We questioned whether individuals with long-standing type 1 diabetes and low or absent C-peptide secretory capacity retained the ability to make proinsulin. RESEARCH DESIGN AND METHODS C-peptide and proinsulin were measured in fasting and stimulated sera from 319 subjects with long-standing type 1 diabetes (‡3 years) and 12 control subjects without diabetes. We considered three categories of stimulated C-peptide: 1) 1Department of Pediatrics, Indiana University ‡ 2 School of Medicine, Indianapolis, IN C-peptide positive, with high stimulated values 0.2 nmol/L; ) C-peptide posi- 2 tive, with low stimulated values ‡0.017 but <0.2 nmol/L; and 3)C-peptide Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indian- <0.017 nmol/L.
    [Show full text]
  • Clinical Policy: Mecasermin (Increlex) Reference Number: ERX.SPA.209 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log
    Clinical Policy: Mecasermin (Increlex) Reference Number: ERX.SPA.209 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Mecasermin (Increlex®) is an insulin growth factor-1 (IGF-1) analogue. FDA Approved Indication(s) Increlex is indicated for the treatment of growth failure in children with severe primary IGF-1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. Limitation(s) of use: Increlex is not a substitute to GH for approved GH indications. Policy/Criteria Provider must submit documentation (which may include office chart notes and lab results) supporting that member has met all approval criteria It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Increlex is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Severe Primary IGF-1 Deficiency (must meet all): 1. Diagnosis of IGF-1 deficiency growth failure and associated growth failure with one of the following (a or b): a. Severe primary IGF-1 deficiency as defined by all (i through iii): i. Height standard deviation score (SDS) ≤ –3.0; ii. Basal IGF-1 SDS ≤ –3.0; iii. Normal or elevated GH level; b. GH gene deletion with development of neutralizing antibodies to GH; 2. Prescribed by or in consultation with an endocrinologist; 3. Age ≥ 2 and <18 years; 4. At the time of request, member does not have closed epiphyses; 5. Dose does not exceed 0.12 mg/kg twice daily.
    [Show full text]
  • Insulin Products and the Cost of Diabetes Treatment
    November 19, 2018 Insulin Products and the Cost of Diabetes Treatment Insulin is a hormone that regulates the storage and use of would involve a consistent insulin level between meals sugar (glucose) by cells in the body. When the pancreas combined with a mealtime level of insulin that has a rapid does not make enough insulin (type 1 diabetes) or it cannot onset and duration of action to match the glucose peak that be used effectively (type 2 diabetes), sugar builds up in the occurs after a meal. The original insulin, also called regular blood. This may lead to serious complications, such as heart insulin, is a short-acting type of product with a duration of disease, stroke, blindness, kidney failure, amputation of action of about 8 hours, making it less suitable for toes, feet, or limbs. Prior to the discovery of insulin providing 24-hour coverage. treatment, type 1 diabetics usually died from this disease. In the late 1930s through the 1950s, regular insulin was There were 23.1 million diagnosed cases of diabetes in the altered by adding substances (protamine and zinc) to gain United States in 2015 according to the Centers for Disease longer action; these are called intermediate-acting insulins. Control and Prevention (CDC). Adding an estimated 7.2 One such advance (neutral protamine Hagedorn, or NPH) million undiagnosed cases brings the total to 30.3 million was patented in 1946 and is still in use today. It allowed for (9.4% of U.S. population). People with type 1 diabetes, the combination of two types of insulin in premixed vials about 5% of U.S.
    [Show full text]
  • Distinct States of Proinsulin Misfolding in MIDY
    bioRxiv preprint doi: https://doi.org/10.1101/2021.05.10.442447; this version posted May 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Distinct states of proinsulin misfolding in MIDY Leena Haataja1, Anoop Arunagiri1, Anis Hassan1, Kaitlin Regan1, Billy Tsai2, Balamurugan Dhayalan3, Michael A. Weiss3, Ming Liu1,4, and Peter Arvan*1 From: 1The Division of Metabolism, Endocrinology & Diabetes and 2Department of Cell & Developmental Biology, University of Michigan Medical Center, Ann Arbor MI 48105; 3Department of Biochemistry and Molecular Biology, Indiana University, Indianapolis, IN 46202; 4Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin 300052, China *To whom correspondence may be addressed: Peter Arvan MD PhD ORCID ID: http://orcid.org/0000-0002-4007-8799 Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Brehm Tower rm 5112 1000 Wall St. Ann Arbor, MI 48105 email: [email protected] FAX: 734-232-8162 Running Title. Proinsulin Disulfide Mispairing Key Words. endoplasmic reticulum, disulfide bonds, protein trafficking, insulin, diabetes Abbreviations. ER, endoplasmic reticulum; MIDY, Mutant INS-gene induced Diabetes of Youth 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.05.10.442447; this version posted May 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract A precondition for efficient proinsulin export from the endoplasmic reticulum (ER) is that proinsulin meets ER quality control folding requirements, including formation of the Cys(B19)-Cys(A20) “interchain” disulfide bond, facilitating formation of the Cys(B7)-Cys(A7) bridge.
    [Show full text]
  • Amylin: Pharmacology, Physiology, and Clinical Potential
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2015 Amylin: Pharmacology, Physiology, and Clinical Potential Hay, Debbie L ; Chen, Steve ; Lutz, Thomas A ; Parkes, David G ; Roth, Jonathan D Abstract: Amylin is a pancreatic ฀-cell hormone that produces effects in several different organ systems. Here, we review the literature in rodents and in humans on amylin research since its discovery as a hormone about 25 years ago. Amylin is a 37-amino-acid peptide that activates its specific receptors, which are multisubunit G protein-coupled receptors resulting from the coexpression of a core receptor protein with receptor activity-modifying proteins, resulting in multiple receptor subtypes. Amylin’s major role is as a glucoregulatory hormone, and it is an important regulator of energy metabolism in health and disease. Other amylin actions have also been reported, such as on the cardiovascular system or on bone. Amylin acts principally in the circumventricular organs of the central nervous system and functionally interacts with other metabolically active hormones such as cholecystokinin, leptin, and estradiol. The amylin-based peptide, pramlintide, is used clinically to treat type 1 and type 2 diabetes. Clinical studies in obesity have shown that amylin agonists could also be useful for weight loss, especially in combination with other agents. DOI: https://doi.org/10.1124/pr.115.010629 Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-112571 Journal Article Published Version Originally published at: Hay, Debbie L; Chen, Steve; Lutz, Thomas A; Parkes, David G; Roth, Jonathan D (2015).
    [Show full text]